|
| | Publication Year | Title | Author(s) |
| 81 | Aug-2016 | TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer. | Ferraro, D; Goldstein, D; O'Connell, R L; Zalcberg, J R; Sjoquist, K M; Tebbutt, Niall C ; Grimison, P; McLachlan, S; Lipton, L L; Vasey, P; Gebski, V J; Aiken, C; Cronk, M; Ng, S ; Karapetis, C S; Shannon, J |
| 82 | 15-May-2016 | Fc-γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer. | Liu, Geoffrey; Tu, Dongsheng; Lewis, Marcia; Cheng, Dangxiao; Sullivan, Leslie A; Chen, Zhuo; Morgen, Eric; Simes, John; Price, Timothy J; Tebbutt, Niall C ; Shapiro, Jeremy D; Jeffery, G Mark; Mellor, J Daniel; Mikeska, Thomas; Virk, Shakeel; Shepherd, Lois E; Jonker, Derek J; O'Callaghan, Christopher J ; Zalcberg, John R; Karapetis, Christos S; Dobrovic, Alexander |
| 83 | May-2016 | Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015. | Price, Timothy J; Thavaneswaran, Subotheni; Burge, Matthew; Segelov, Eva; Haller, Daniel G; Punt, Cornelis Ja; Arnold, Dirk; Karapetis, Christos S; Tebbutt, Niall C ; Pavlakis, Nick; Gibbs, Peter; Shapiro, Jeremy D |
| 84 | Mar-2016 | Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial | Tebbutt, Niall C ; Price, Timothy J; Ferraro, Danielle A; Wong, Nicole; Veillard, Anne-Sophie; Hall, Merryn; Sjoquist, Katrin M; Pavlakis, Nick; Strickland, Andrew; Varma, Suresh C; Cooray, Prasad; Young, Rosemary; Underhill, Craig; Shannon, Jennifer A; Ganju, Vinod; Gebski, Val J |
| 85 | 10-Jan-2016 | Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. | Renfro, Lindsay A; Loupakis, Fotios; Adams, Richard A; Seymour, Matthew T; Heinemann, Volker; Schmoll, Hans-Joachim; Douillard, Jean-Yves; Hurwitz, Herbert; Fuchs, Charles S; Diaz-Rubio, Eduardo; Porschen, Rainer; Tournigand, Christophe; Chibaudel, Benoist; Falcone, Alfredo; Tebbutt, Niall C ; Punt, Cornelis J A; Hecht, J Randolph; Bokemeyer, Carsten; Van Cutsem, Eric; Goldberg, Richard M; Saltz, Leonard B; de Gramont, Aimery; Sargent, Daniel J; Lenz, Heinz-Josef |
| 86 | Jan-2016 | Symptom clusters in advanced cancer patients: an empirical comparison of statistical methods and the impact on quality of life | Dong, Skye T; Costa, Daniel SJ; Butow, Phyllis N; Lovell, Melanie R; Agar, Meera; Velikova, Galina; Teckle, Paulos; Tong, Allison; Tebbutt, Niall C ; Clarke, Stephen J; van der Hoek, Kim; King, Madeleine T; Fayers, Peter M |
| 87 | 14-Aug-2015 | Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature. | Chan, David L; Pavlakis, Nick; Shapiro, Jeremy; Price, Timothy J; Karapetis, Christos S; Tebbutt, Niall C ; Segelov, Eva |
| 88 | 17-Mar-2015 | Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer. | Price, Timothy J; Bruhn, M A; Lee, C K; Hardingham, J E; Townsend, A R; Mann, K P; Simes, J; Weickhardt, A ; Wrin, J W; Wilson, K; Gebski, V; Van Hazel, G; Robinson, B; Cunningham, D; Tebbutt, Niall C |
| 89 | 15-Mar-2015 | Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. | Tebbutt, Niall C ; Kotasek, Dusan; Burris, Howard A; Schwartzberg, Lee S; Hurwitz, Herbert; Stephenson, Joe; Warner, Douglas J; Chen, Lisa; Hsu, Cheng-Pang; Goldstein, David B |
| 90 | 21-Nov-2014 | RHOA inactivation enhances Wnt signalling and promotes colorectal cancer. | Rodrigues, Paulo; Macaya, Irati; Bazzocco, Sarah; Mazzolini, Rocco; Andretta, Elena; Dopeso, Higinio; Mateo-Lozano, Silvia; Bilić, Josipa; Cartón-García, Fernando; Nieto, Rocio; Suárez-López, Lucia; Afonso, Elsa; Landolfi, Stefania; Hernandez-Losa, Javier; Kobayashi, Kazuto; Cajal, Santiago Ramón Y; Tabernero, Josep; Tebbutt, Niall C ; Mariadason, John M ; Schwartz, Simo; Arango, Diego |
| 91 | 10-Nov-2014 | Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. | Shi, Qian; de Gramont, Aimery; Grothey, Axel; Zalcberg, John; Chibaudel, Benoist; Schmoll, Hans-Joachim; Seymour, Matthew T; Adams, Richard A; Saltz, Leonard; Goldberg, Richard M; Punt, Cornelis J A; Douillard, Jean-Yves; Hoff, Paulo M; Hecht, Joel Randolph; Hurwitz, Herbert; Díaz-Rubio, Eduardo; Porschen, Rainer; Tebbutt, Niall C ; Fuchs, Charles; Souglakos, John; Falcone, Alfredo; Tournigand, Christophe; Kabbinavar, Fairooz F; Heinemann, Volker; Van Cutsem, Eric; Bokemeyer, Carsten; Buyse, Marc; Sargent, Daniel J |
| 92 | 29-Jul-2014 | The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials. | Segelov, E; Chan, David L; Shapiro, J; Price, Timothy J; Karapetis, C S; Tebbutt, Niall C ; Pavlakis, N |
| 93 | 11-Jun-2014 | Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer. | Van Cutsem, Eric; Eng, Cathy; Nowara, Elzbieta; Swieboda-Sadlej, Anna; Tebbutt, Niall C ; Mitchell, Edith; Davidenko, Irina; Stephenson, Joe; Elez, Elena; Prenen, Hans; Deng, Hongjie; Tang, Rui; McCaffery, Ian; Oliner, Kelly S; Chen, Lisa; Gansert, Jennifer; Loh, Elwyn; Smethurst, Dominic; Tabernero, Josep |
| 94 | 12-Dec-2013 | Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer. | Jonker, D J; Karapetis, C S; Harbison, C; O'Callaghan, Christopher J ; Tu, D; Simes, R J; Malone, D P; Langer, C; Tebbutt, Niall C ; Price, Timothy J; Shapiro, J; Siu, L L; Wong, R P W; Bjarnason, G; Moore, M J; Zalcberg, John R; Khambata-Ford, S |
| 95 | 3-Dec-2013 | Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. | Greenhalf, William; Ghaneh, Paula; Neoptolemos, John P; Palmer, Daniel H; Cox, Trevor F; Lamb, Richard F; Garner, Elizabeth; Campbell, Fiona; Mackey, John R; Costello, Eithne; Moore, Malcolm J; Valle, Juan W; McDonald, Alexander C; Carter, Ross; Tebbutt, Niall C ; Goldstein, David B; Shannon, Jennifer; Dervenis, Christos; Glimelius, Bengt; Deakin, Mark; Charnley, Richard M; Lacaine, François; Scarfe, Andrew G; Middleton, Mark R; Anthoney, Alan; Halloran, Christopher M; Mayerle, Julia; Oláh, Attila; Jackson, Richard; Rawcliffe, Charlotte L; Scarpa, Aldo; Bassi, Claudio; Büchler, Markus W |
| 96 | 8-Nov-2013 | The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: results from the Australasian phase III MAX study. | Carter, Hannah E; Zannino, Diana; John Simes, R; Schofield, Deborah J; Howard, Kirsten; Zalcberg, John R; Price, Timothy J; Tebbutt, Niall C |
| 97 | 4-Nov-2013 | BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition. | Andrews, Miles C; Behren, Andreas; Chionh, Fiona; Mariadason, John M ; Vella, Laura J; Do, Hongdo; Dobrovic, Alexander ; Tebbutt, Niall C ; Cebon, Jonathan S |
| 98 | 16-Sep-2013 | Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. | Ohtsu, Atsushi; Ajani, Jaffer A; Bai, Yu-Xian; Bang, Yung-Jue; Chung, Hyun-Cheol; Pan, Hong-Ming; Sahmoud, Tarek; Shen, Lin; Yeh, Kun-Huei; Chin, Keisho; Muro, Kei; Kim, Yeul Hong; Ferry, David; Tebbutt, Niall C ; Al-Batran, Salah-Eddin; Smith, Heind; Costantini, Chiara; Rizvi, Syed; Lebwohl, David; Van Cutsem, Eric |
| 99 | 16-Aug-2013 | Targeting the ERBB family in cancer: couples therapy. | Tebbutt, Niall C ; Pedersen, Mikkel W; Johns, Terrance G |
| 100 | 14-Feb-2013 | Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial. | Tebbutt, Niall C ; Parry, M M; Zannino, D; Strickland, A H; Van Hazel, G A; Pavlakis, N; Ganju, V; Mellor, D; Dobrovic, Alexander ; Gebski, V J |
Loading...
2
0
20
0
false